US › Healthcare

CorMedix Inc (CRMD)

US · Healthcare · Biotechnology

$7.52-0.40%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$127.4M

Revenue YoY

+226.1%

Net profit

$38.6M

Profit YoY

+87.0%

EPS

$0.35

EPS estimate

$0.33

Net margin

30.3%

EPS came in at 0.35 against a street estimate of 0.33 — a beat of 6.1%.

Key statistics

Market cap

$590.7M

P/E

3.5

Forward P/E

14.8

P/B

1.35

Book value

$5.58

EPS (TTM)

$2.17

52-week high

$14.96

52-week low

$6.12

50-day MA

$8.28

200-day MA

$8.64

Beta

1.48

Analyst view

Analysts rate CorMedix Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $15.00.

Shareholding

Insiders

7.53%

Institutions

54.62%

Largest institutional holders

Fund	Stake
Deep Track Capital, LP	8.00%
BlackRock Inc	7.61%
Vanguard Capital Management, LLC	3.99%
State Street Corp	2.79%
Royce & Associates, LP	2.41%
Geode Capital Management, LLC	2.32%
UBS Group AG	1.96%
Oberweis Asset Management Inc	1.54%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for CorMedix Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.